Comparison of incretin-based drugs: clinical advantage of GLP-1 analogue liraglutide
10.3760/cma.j.issn.1000-6699.2012.09.022
- VernacularTitle:基于肠促胰素治疗的药物比较:GLP-1类似物利拉鲁肽的临床优势
- Author:
Yiming MU
- Publication Type:Journal Article
- Keywords:
Incretin;
Liraglutide;
Sitagliptin;
Diabetes mellitus,type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2012;28(9):后插8-后插11
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4)inhibitors are two classes of incretin-based drugs for type 2 diabetes treatment.GLP-1 receptor agonists can directly activate the GLP-1 receptor while DPP-4 inhibitors act indirectly via preventing incretin enzymatic degradation.The comparison of two classes of drugs in clinical use becomes a hot research topic.A head to head comparison study has shown that,compared with DPP-4 inhibitor sitagliptin,GLP-1 analogue liraglutide shows better blood glucose control,weight loss,and β-cell function improvement,as well as higher patient treatment satisfaction and better cost-effectiveness of drug economics.Those advantages of liraglutide provide an ideal choice for the clinical treatment of patients with type 2 diabetes.
